Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IPrEP Study #2: Enhanced PrEP for Young Female Sex Workers in Kenya
NCT03988387Completed
- Sponsor
- Columbia University
- Start
- Oct 2019
- Primary completion
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of emtricitabine + tenofovir disoproxil in human immunodeficiency virus infection (HIV) (2 arms), sponsored by Columbia University. Primary endpoint: PrEP Adherence between PS and RRT arms at 12 months. Started Oct 2019; status: completed.
02
Drugs
emtricitabine + tenofovir disoproxil
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT03988387.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03988387.